On this page
How should CTD A.2 explain adventitious-agent safety?
Connect the relevant material and cell-substrate origins, prevention measures, testing and process-evaluation evidence into a scoped safety assessment. Address viral and nonviral questions with appropriate sources. Identify what each control can establish and the uncertainty that remains; a negative test or supplier certificate is not a universal absence-of-agent conclusion.
Before you begin
M4Q(R1) A.2; Q5A(R2) applies to its defined biotechnology-product scope and does not cover every nonviral agent or every product class.
What you will prepare: A source-to-control assessment with evidence links and explicit limitations for the actual materials and process.
Separate viral and nonviral questions
Inventory relevant biological materials, cell substrates, excipients and process exposures using S.2.3 and P.4.5. Establish their sources and the actual process in which they are used. M4Q's A.2 includes nonviral as well as viral adventitious-agent questions. Q5A(R2) addresses viral safety within its product scope; its definition excludes unconventional transmissible agents such as prions, so it cannot be cited as a complete TSE assessment.
Build a working risk-to-evidence map: potential source/agent, applicability rationale, prevention or control, testing/evaluation evidence, process location and remaining uncertainty. Have the relevant safety/microbiology specialists own the scientific assessment. Unknown material origin keeps the affected conclusion undetermined, even when finished-product tests are negative.
Connect material and testing evidence to the manufacturing process
For relevant biological materials, present the information supporting source safety and qualification. Where cell banks are used, link their derivation, testing and qualification to the bank actually supporting production. Explain the selection and location of viral testing through the process, including the applicable unprocessed-bulk information, with methods and results traceable to the records.
Discuss nonviral prevention/control separately, using appropriate evidence for the material and agent: relevant origin certifications, testing and process controls may contribute. State the scope and limitations of certificates and assays. A negative result does not establish the absence of every possible agent, and a supplier certificate cannot answer questions outside its tested or certified scope.
Explain clearance studies and the limits of their interpretation
Present the rationale, study plan, results and evaluation of viral clearance where applicable. Identify the process version, model viruses and steps evaluated; explain how the study model relates to the proposed process. Keep removal and inactivation mechanisms and the evidence for the overall interpretation visible. Use the applicable Q5A(R2) evaluation and limitations sections with the responsible specialist; do not add reduction factors mechanically without considering what the experiments demonstrate.
Fictional exercise: a purification parameter changes beyond the conditions evaluated in the clearance model. The author should identify the affected step and ask for an assessment of model relevance and any additional work. Until resolved, qualify the conclusion and reconcile S.2/P.3. Copying the old total clearance figure into the new process narrative would imply support that has not been established.
Make each safety conclusion traceable to a control
Organize the writing around the source of a potential concern and the evidence addressing it. The following editorial matrix helps specialists review coverage; it does not prescribe a complete testing program.
| Evidence layer | Record to identify | Limit to explain |
|---|---|---|
| Material or substrate origin | Actual source, history and relevant qualification | Unknown or changed origin cannot be closed by assumption |
| Prevention and selection | Defined sourcing and process controls | What those measures address and what they do not |
| Testing | Sample location, method, scope and results | Detection and sampling limitations relevant to interpretation |
| Process clearance | Evaluated steps, model and conditions | Relationship to the process actually proposed |
| Overall assessment | Scientific rationale across the evidence | Residual questions and dependencies on specific conditions |
Review exercise: a supplier changes the origin of a biological material but the finished-product test remains negative. Identify which source qualification and process assumptions depended on the previous material. Have the appropriate specialists assess the change rather than treating the final result as proof that all upstream risks are unchanged.
For viral clearance, keep the contribution of each evaluated step and the model's relevance visible. Combining reduction factors requires a supported scientific interpretation; an arithmetic total alone can hide dependence between steps or conditions outside the evaluated range.
Connect S.2 material controls and P.4 excipient origin to this assessment. Q5A(R2)'s viral-safety scope does not cover every nonviral concern. Preserve separate appropriate evidence for questions outside that scope.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a negative test prove that no adventitious agent is present?
No. Interpret a result within the sample, method and detection scope, alongside sourcing and process controls. The overall assessment should explain the combined evidence and its limitations. A negative observation cannot establish absence of every potential agent under every condition.
Can viral clearance reduction factors simply be added?
Do not present an arithmetic total without the supporting scientific assessment of the evaluated steps and model. Identify process conditions, mechanisms and the evidence supporting the overall interpretation. A changed process or unsupported relationship between steps can affect what the studies demonstrate.
Does Q5A(R2) provide a complete assessment for prion concerns?
No. Q5A(R2) addresses viral safety within its defined scope and excludes unconventional transmissible agents such as prions from its virus definition. Identify the relevant nonviral concern and use appropriate evidence and specialist assessment rather than treating a viral-safety conclusion as comprehensive.
What changes can make an existing clearance discussion need review?
Changes to material origin, the process or evaluated operating conditions can affect the relevance of the supporting evidence. Identify the affected assumptions and obtain the scientific assessment. Reusing the previous total or conclusion without explaining the relationship can overstate what has been demonstrated.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.A.2, printed pages 16–17.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.A.2. A heading identifies placement, not mandatory applicability.